Studies in vitro e in vivo of Phage Therapy Medical Products (PTMPs) targeting clinical strains of Klebsiella pneumoniae belonging to the clone ST512

Ines Bleriot,Lucia Blasco,Patricia Fernandez-Grela,Laura Fernandez-Garcia,Lucia Arman,Clara Ibaguren-Quiles,Concha Ortiz-Cartagena,Antonio Barrio-Pujante,Jose Ramon Pano Pardo,Jesus Oteo-Iglesias,Maria Tomas

DOI: https://doi.org/10.1101/2024.11.20.624559

2024-11-22

Abstract:The widespread incidence of antimicrobial resistance has created renewed interest in the use of alternative antimicrobial treatments such as phage therapy. Phages are viruses that infect bacteria and generally have a narrow bacteria host-range. Combining phages with antibiotics can prevent the emergence of bacterial resistance. The aim of the present study was to develop phage therapy medical products (PTMPs) targeting clinical isolates of carbapenems-producing Klebsiella pneumoniae belonging to the high-risk clone ST512. From a collection of twenty-two seed of lytic phages sequenced belonging to MePRAM collection, four were used to generate PTMPs (CAC_Kpn1 and CAC_Kpn2). These PTMPs were partly active against three of the clinical strains of clone ST512 (A, B and C). The use of Appelmans method in the CAC_Kpn1_ad (adaptedCAC_Kpn1) yielded a significant increase in the efficacy against strain A, while adapted CAC_Kpn2 (CAC_Kpn2_ad) only effectively reduced bacterial survival when combined with 1/2; x MIC Beta-lactam antibiotic meropenem for 24 h in clinical strains B and C, showed after this time, resistance to PTMPs. In addition, the amounts of endotoxin released by the PTMPs were quantified and subsequently reduced in preparation for in vivo use of the PTMPs in Galleria mellonella infection model confirming the in vitro results from the CAC_Kpn1_ad and CAC_Kpn2_ad.

Biology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to develop phage therapy medical products (PTMPs) for high - risk clone ST512 of Klebsiella pneumoniae that produces carbapenemase. Specifically, the research objectives include:

1. **Develop PTMPs**: Screen phages with a broad host range from the MePRAM collection to generate two PTMPs (CAC_Kpn1 and CAC_Kpn2), targeting three clinically isolated ST512 clone strains (A, B, and C) respectively.

2. **Improve the efficacy of PTMPs**: Adaptively improve PTMPs through the Appelmans method (phage training) to increase their infection efficiency against target strains and reduce the emergence of bacterial resistance.

3. **Combined use with antibiotics**: Study the synergistic effect (Phage - Antibiotic Synergy, PAS) of PTMPs combined with the semi - lethal concentration of the β - lactam antibiotic meropenem to further improve the treatment effect.

4. **Evaluate safety**: Quantify and reduce the amount of endotoxin released during the use of PTMPs to ensure their safety in animal models.

5. **Verify efficacy**: Verify the efficacy of PTMPs in in vitro and in vivo experiments through the Galleria mellonella (wax moth larvae) infection model.

### Main research contents

- **Selection and identification of phages**: Screen 4 phages with a broad host range from 22 lytic phages for generating PTMPs.
- **Generation and adaptive improvement of PTMPs**: Adaptively improve PTMPs through the Appelmans method to increase their infection efficiency against target strains.
- **In vitro experiments**: Evaluate the infection efficiency and antibacterial effect of PTMPs and their adaptively improved PTMPs (CAC_Kpn1_ad and CAC_Kpn2_ad) against target strains.
- **Combined treatment**: Study the synergistic effect of PTMPs combined with meropenem and evaluate their inhibitory effect on bacterial growth.
- **Removal and quantification of endotoxin**: Ensure the safety of PTMPs in animal models.
- **In vivo experiments**: Verify the efficacy and safety of PTMPs in vivo through the Galleria mellonella infection model.

### Research background

With the widespread emergence of antimicrobial drug resistance, the need to find alternative antibacterial treatment methods is becoming increasingly urgent. Phage therapy, as a potential solution, has the advantages of high host specificity and low cost. However, the co - evolution between phages and bacteria may lead to bacterial resistance to phages, which is one of the main challenges faced by phage therapy. Therefore, developing PTMPs and improving efficacy through phage training and combined antibiotic use has become the focus of current research.